TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30540689

Group type: EXPERIMENTAL
Intervention: Minimally invasive intervention (percutaneous transluminal cerebral angioplasty and stenting)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (intravenous thrombolysis with urokinase)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 30184455

Group type: EXPERIMENTAL
Intervention: Baloxavir (40 or 80 mg)
Number of subjects: 1064

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1064

Group type: COMPARATOR
Intervention: Oseltamivir (75 mg twice daily for 5 days)
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: Baloxavir
Number of subjects: 1064

Group type: COMPARATOR
Intervention: Oseltamivir
Number of subjects: 1064
Study: 27596224

Group type: EXPERIMENTAL
Intervention: Practice facilitation (PF) intervention
Number of subjects: 54085

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 54085
Study: 24999213

Group type: EXPERIMENTAL
Intervention: Buscopan (20 mg intravenously)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 116
Study: 22173517

Group type: EXPERIMENTAL
Intervention: Selective digestive decontamination (SDD) with oral gentamicin (80 mg 4 times per day) and oral polymyxin E gel (0.5 g 4 times per day) for 7 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (oral placebo gel and 2 placebo oral solutions 4 times per day for 7 days)
Number of subjects: 40
Study: 20350641

Group type: EXPERIMENTAL
Intervention: 17-alpha-hydroxyprogesterone caproate (17P) in no-cerclage group
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 17-alpha-hydroxyprogesterone caproate (17P) in cerclage group
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control (no 17P) in cerclage group
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control (no 17P) in no-cerclage group
Number of subjects: 300
Study: 17685705

Group type: EXPERIMENTAL
Intervention: Training group (TRN; n = 8)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (CTL; n = 9)
Number of subjects: 17
Study: 21359122

Group type: EXPERIMENTAL
Intervention: Latino version of the curriculum
Number of subjects: 3402

Group type: EXPERIMENTAL
Intervention: Multicultural version of the curriculum
Number of subjects: 3402

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3402
Study: 12435472

Group type: EXPERIMENTAL
Intervention: Opioid blockade (8 mg naloxone i.v.)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo blockade (saline)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Combined groups analysis
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Higher DBP in LBP subjects
Number of subjects: 95
Study: 10352387

Group type: EXPERIMENTAL
Intervention: CC + transdermal estrogen
Number of subjects: 0

Group type: COMPARATOR
Intervention: CC only
Number of subjects: 0
Study: 8687263

Group type: EXPERIMENTAL
Intervention: Computer reminders printed on daily rounds reports about preventive care for which their patients were eligible.
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract).
Number of subjects: 78
Study: 1901071

Group type: EXPERIMENTAL
Intervention: Routine predischarge coronary arteriography (routine catheterization group)
Number of subjects: 1658

Group type: COMPARATOR
Intervention: Selective predischarge coronary arteriography (selective catheterization group)
Number of subjects: 1658
Study: 6138934

Group type: EXPERIMENTAL
Intervention: Propranolol (beta-blockade)
Number of subjects: 0
Study: 31721503

Group type: EXPERIMENTAL
Intervention: Fast expansion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Slow expansion
Number of subjects: 40
Study: 28393258

Group type: EXPERIMENTAL
Intervention: NIV (noninvasive ventilation) for the first 48 hours after extubation
Number of subjects: 144

Group type: COMPARATOR
Intervention: Conventional oxygen treatment (usual care)
Number of subjects: 144
Study: 25418079

Group type: EXPERIMENTAL
Intervention: Nystatin
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Biotène(®) mouthwash Oral Rinse
Number of subjects: 21

Group type: COMPARATOR
Intervention: No medication
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Nystatin vs Biotène(®) mouthwash
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Biotène(®) mouthwash adherence
Number of subjects: 21
Study: 24461526

Group type: EXPERIMENTAL
Intervention: Vitamin A (1,500 IU) and Vitamin D (500 IU) supplementation for 3 months
Number of subjects: 597

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 597
Study: 22526411

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) 250 mg
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) 500 mg
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) 750 mg
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) 1000 mg
Number of subjects: 65
Study: 19400438

Group type: EXPERIMENTAL
Intervention: Perceptual illusion of having two right arms
Number of subjects: 0
Study: 17679311

Group type: EXPERIMENTAL
Intervention: Antidepressant medications
Number of subjects: 0
Study: 15221178

Group type: EXPERIMENTAL
Intervention: Treadmill training with body-weight support for 1.5-3 months
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Backward stepping training for 2-3 weeks
Number of subjects: 6

Group type: COMPARATOR
Intervention: Untrained backward stepping on treadmill
Number of subjects: 6

Group type: COMPARATOR
Intervention: Untrained stepping in place on idle treadmill
Number of subjects: 6
Study: 11787914

Group type: EXPERIMENTAL
Intervention: Vaginal administration of misoprostol (400 microg initial dose, followed by 200 microg two hours later and then four-hourly 200 microg doses)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Oral administration of misoprostol (400 microg initial dose, followed by 200 microg two hours later and then four-hourly 200 microg doses)
Number of subjects: 55
Study: 9422305

Group type: EXPERIMENTAL
Intervention: Ketoprofen 1.4 mg x kg(‐1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ketorolac 0.4 mg x kg(‐1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Diclofenac 1.1 mg x kg(‐1)
Number of subjects: 10
Study: 8230896

Group type: EXPERIMENTAL
Intervention: Amlexanox
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 15
Study: 2984397

Group type: EXPERIMENTAL
Intervention: Intralipid (1 gm/kg over 12 hours, every other day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 0
Study: 31248404

Group type: EXPERIMENTAL
Intervention: More intensive lifestyle modification programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Less intensive lifestyle modification programme
Number of subjects: 0
Study: 29227578

Group type: EXPERIMENTAL
Intervention: Pioglitazone plus exenatide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basal/bolus insulin therapy
Number of subjects: 0
Study: 25751000

Group type: EXPERIMENTAL
Intervention: Collaborative & Proactive Solutions (CPS)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Parent Management Training (PMT)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Waitlist Control (WLC)
Number of subjects: 134
Study: 24315894

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 13455

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 13455

Group type: EXPERIMENTAL
Intervention: Rivaroxaban and Warfarin
Number of subjects: 13455
Study: 24339687

Group type: EXPERIMENTAL
Intervention: Lea symbols
Number of subjects: 47

Group type: COMPARATOR
Intervention: Bailey-Lovie tumbling E chart
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Inter-eye differences
Number of subjects: 47
Study: 20544158

Group type: EXPERIMENTAL
Intervention: Dry needle stimulation to a right supraspinatus trigger point (C4,5)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham intramuscular dry needle puncture (Control)
Number of subjects: 40
Study: 18793221

Group type: COMPARATOR
Intervention: Control group (no ultrafiltration)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Hemofiltration with constant flow of 300 mL/m²/min and filtrate volume of 3000 mL
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Dialysis added to hemofiltration
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Other filtration strategies (not specified)
Number of subjects: 35
Study: 16472379

Group type: EXPERIMENTAL
Intervention: Lumbopelvic manipulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternative lumbar manipulation technique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-thrust lumbar mobilization technique
Number of subjects: 0
Study: 12787969

Group type: EXPERIMENTAL
Intervention: CEE (conjugated equine estrogens 0.625 mg)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: CEE/MPA (conjugated equine estrogens 0.625 mg plus medroxyprogesterone acetate 5 mg)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: E(2)/NETA (17beta‐estradiol 2 mg plus norethisterone acetate 1 mg)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (women who declined or did not qualify for treatment)
Number of subjects: 121
Study: 10951147

Group type: EXPERIMENTAL
Intervention: Cyclosporin (4 mg kg‐1 daily for 4 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Open-label cyclosporin (after randomized trial)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cyclosporin treatment
Number of subjects: 30
Study: 8838437

Group type: EXPERIMENTAL
Intervention: Sustained-release tramadol (100 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sustained-release tramadol (200 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sustained-release tramadol (100 mg and 200 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sustained-release tramadol
Number of subjects: 20
Study: 1468244

Group type: EXPERIMENTAL
Intervention: CR dihydrocodeine (60 mg) tablets (1 tablet twice daily to 2 tablets daily)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Combination dextropropoxyphene (32.5 mg)/paracetamol (325 mg) tablets (2 tablets 3‐times daily to 2 tablets 4‐times daily)
Number of subjects: 86
Study: 6988959

Group type: EXPERIMENTAL
Intervention: Intermittent Mandatory Ventilation (IMV)
Number of subjects: 36
Study: 30905495

Group type: EXPERIMENTAL
Intervention: Relative Motion Extension (RME) program
Number of subjects: 42

Group type: COMPARATOR
Intervention: Controlled Active Motion (CAM) program
Number of subjects: 42
Study: 29957886

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 85

Group type: COMPARATOR
Intervention: Gliclazide
Number of subjects: 85
Study: 28012819

Group type: EXPERIMENTAL
Intervention: Bimatoprost SR (6 μg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Bimatoprost SR (10 μg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Bimatoprost SR (15 μg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Bimatoprost SR (20 μg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Topical bimatoprost 0.03%
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Bimatoprost SR
Number of subjects: 75

Group type: COMPARATOR
Intervention: Topical bimatoprost
Number of subjects: 75
Study: 26497960

Group type: COMPARATOR
Intervention: Diesel exhaust (DE) exposure for 2 hours with a particulate matter concentration of 300 μg/m(3)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Ambient air (AA) exposure for 2 hours
Number of subjects: 18
Study: 23578679

Group type: EXPERIMENTAL
Intervention: Patients with significant disability progression (SDP) at 5 years
Number of subjects: 180

Group type: COMPARATOR
Intervention: Patients without significant disability progression (SDP) at 5 years
Number of subjects: 180
Study: 21317176

Group type: EXPERIMENTAL
Intervention: Sheltered biopsy forceps
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard unsheathed biopsy forceps
Number of subjects: 27
Study: 19528562

Group type: EXPERIMENTAL
Intervention: Red yeast rice, 1800 mg twice daily for 24 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo, twice daily for 24 weeks
Number of subjects: 62
Study: 17530404

Group type: EXPERIMENTAL
Intervention: Random Controlled Trial (RCT) design for evaluating sexual offender treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RCT study by Marques et al.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternative strategies for evaluating treatment
Number of subjects: 0
Study: 17151968

Group type: EXPERIMENTAL
Intervention: GIK solution (500 ml of 30% dextrose solution, containing 100 IU insulin and 80 mEq of potassium, at a rate of 1 ml x kg (‐1) x h (‐1))
Number of subjects: 49

Group type: COMPARATOR
Intervention: 5% dextrose (control group)
Number of subjects: 49
Study: 14615106

Group type: EXPERIMENTAL
Intervention: Oral cannabis extract (n=211)
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Delta9-tetrahydrocannabinol (Delta9-THC; n=206)
Number of subjects: 667

Group type: COMPARATOR
Intervention: Placebo (n=213)
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Patient-reported spasticity and pain
Number of subjects: 667
Study: 10338218

Group type: EXPERIMENTAL
Intervention: Structured triglycerides
Number of subjects: 19

Group type: COMPARATOR
Intervention: Long-chain triglycerides (LCT)
Number of subjects: 19
Study: 7856528

Group type: EXPERIMENTAL
Intervention: bucindolol
Number of subjects: 30

Group type: COMPARATOR
Intervention: metoprolol
Number of subjects: 30
Study: 2392497

Group type: EXPERIMENTAL
Intervention: Caffeine (1 mg/kg)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Caffeine (2 mg/kg)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Caffeine (4 mg/kg)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Caffeine (various doses)
Number of subjects: 2
Study: 6453240

Group type: EXPERIMENTAL
Intervention: Manipulation therapy
Number of subjects: 95

Group type: COMPARATOR
Intervention: Soft-tissue massage
Number of subjects: 95
Study: 31954707

Group type: EXPERIMENTAL
Intervention: Unscheduled radiologic examination orders
Number of subjects: 700
Study: 29784521

Group type: EXPERIMENTAL
Intervention: Health worker involvement in disclosure process
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Differences in training and involvement in disclosure process among health worker categories
Number of subjects: 73
Study: 27749511

Group type: EXPERIMENTAL
Intervention: Noninvasive neurally adjusted ventilatory assist
Number of subjects: 18
Study: 25708251

Group type: EXPERIMENTAL
Intervention: Smart phone application (SPA) instructions, n=108
Number of subjects: 260

Group type: COMPARATOR
Intervention: Written instructions with visual aids (control group), n=152
Number of subjects: 260
Study: 23527361

Group type: EXPERIMENTAL
Intervention: CAD/CAM surgical guides
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional surgical guides
Number of subjects: 10
Study: 20538669

Group type: EXPERIMENTAL
Intervention: Step-and-shoot (SAS) mode (n=50)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High-pitch mode (n=50)
Number of subjects: 100
Study: 19018915

Group type: EXPERIMENTAL
Intervention: TTT intervention (educational train-the-trainer course plus pharmacotherapy feedback)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Standard education (control group)
Number of subjects: 168
Study: 15958039

Group type: EXPERIMENTAL
Intervention: rHuEPO therapy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 29
Study: 12938567

Group type: EXPERIMENTAL
Intervention: Registry data
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomised trials
Number of subjects: 0
Study: 10481405

Group type: EXPERIMENTAL
Intervention: Influenza patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inpatients without limitations to activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bed-bound inpatients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inpatients with pneumonia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inpatients without pneumonia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inpatients who died within 9 months of the onset of influenza
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inpatients who were alive 9 months after influenza infection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 8602180

Group type: EXPERIMENTAL
Intervention: 30 mg of beta carotene per day and 25,000 IU of retinol (vitamin A) per day
Number of subjects: 18314

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18314
Study: 1943090

Group type: EXPERIMENTAL
Intervention: rHGH (0.2 mg/kg.d)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 7113949

Group type: EXPERIMENTAL
Intervention: Human milk alone
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Human milk with supplemental vitamin D
Number of subjects: 91

Group type: COMPARATOR
Intervention: Similac
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Male infants
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Lactating mothers
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Duration of lactation
Number of subjects: 91
Study: 30702971

Group type: EXPERIMENTAL
Intervention: Celecoxib with neoadjuvant chemotherapy
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Celecoxib with neoadjuvant chemotherapy in PTGS2-low group (n = 100)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Celecoxib use
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Celecoxib in addition to docetaxel
Number of subjects: 156

Group type: COMPARATOR
Intervention: Celecoxib in CALGB 30801 trial
Number of subjects: 156
Study: 28476567

Group type: EXPERIMENTAL
Intervention: Dietary intake (soluble fiber and protein)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Dietary intake (glycemic index, monounsaturated fat, polyunsaturated fat)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Total daily insulin dose per kilogram
Number of subjects: 98
Study: 25872531

Group type: EXPERIMENTAL
Intervention: Yellow fever (YF) vaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Innate immune response characterization
Number of subjects: 0
Study: 23645323

Group type: EXPERIMENTAL
Intervention: Ramipril monotherapy
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Combination therapy (34% of children)
Number of subjects: 38
Study: 21432712

Group type: EXPERIMENTAL
Intervention: Toilet advertisement
Number of subjects: 200

Group type: COMPARATOR
Intervention: Rubbish advertisement
Number of subjects: 200
Study: 19751151

Group type: EXPERIMENTAL
Intervention: Mixed gB infection
Number of subjects: 239

Group type: COMPARATOR
Intervention: Single genotype infection
Number of subjects: 239

Group type: COMPARATOR
Intervention: gB genotype
Number of subjects: 239
Study: 17715115

Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced MRI
Number of subjects: 115
Study: 15023093

Group type: EXPERIMENTAL
Intervention: Eating Disorder Diagnostic Scale (HDDS)
Number of subjects: 0
Study: 11262466

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 4589

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4589
Study: 9037342

Group type: EXPERIMENTAL
Intervention: In-home educational intervention conducted by lay health workers (LHWs)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 321
Study: 7507308

Group type: EXPERIMENTAL
Intervention: Bladder neck incision (44 unilateral, 60 bilateral)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Bladder neck incision (unilateral)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Bladder neck incision (bilateral)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Bladder neck incision
Number of subjects: 104
Study: 3090583

Group type: EXPERIMENTAL
Intervention: A + N (alcohol and nicotine)
Number of subjects: 24

Group type: COMPARATOR
Intervention: A + O (alcohol and smoking placebo)
Number of subjects: 24

Group type: COMPARATOR
Intervention: O + N (Nicotine and placebo drink)
Number of subjects: 24

Group type: COMPARATOR
Intervention: O + O (no drugs)
Number of subjects: 24
Study: 30348630

Group type: EXPERIMENTAL
Intervention: Mobile videoconferencing intervention for 4 weeks
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: In-person intervention for 4 weeks
Number of subjects: 81

Group type: COMPARATOR
Intervention: Self-care intervention for 4 weeks
Number of subjects: 81
Study: 27250845

Group type: EXPERIMENTAL
Intervention: Gel‐200
Number of subjects: 379

Group type: COMPARATOR
Intervention: PBS
Number of subjects: 379
Study: 25040148

Group type: EXPERIMENTAL
Intervention: Non‐Communicating Children's Pain Checklist Postoperative Version (NCCPC‐PV)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Echelle Douleur Enfant San Salvador (DESS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Children's Hospital of Eastern Ontario Pain Scale (CHEOPS)
Number of subjects: 40
Study: 21890335

Group type: EXPERIMENTAL
Intervention: Ciclesonide/Formoterol 320/9 μg bid (CIC/F)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Fluticasone Propionate/Salmeterol 250/50 μg bid (FP/S)
Number of subjects: 160
Study: 20528697

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser (1 W, 10 Hz, 100 mJ, 1064 nm) and EMP
Number of subjects: 21

Group type: COMPARATOR
Intervention: EMP alone (control)
Number of subjects: 21
Study: 18541174

Group type: EXPERIMENTAL
Intervention: Standard vaccination schedule (0, 1, 6 months)
Number of subjects: 1964

Group type: EXPERIMENTAL
Intervention: Accelerated vaccination schedule (0, 1, 2 months)
Number of subjects: 1964

Group type: EXPERIMENTAL
Intervention: Vaccination at screening
Number of subjects: 1964

Group type: EXPERIMENTAL
Intervention: Highly discounted vaccine from local health departments
Number of subjects: 1964
Study: 15805900

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 1015

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 1015
Study: 12867685

Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Netilmicin
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 74